Aurisco Pharmaceutical Co.,Ltd. (SHA:605116)

Market Cap	8.15B -8.1%
Revenue (ttm)	1.68B +9.2%
Net Income	393.72M +0.4%
EPS	0.96 -2.8%
Shares Out	403.41M
PE Ratio	20.98
Forward PE	n/a
Dividend	0.34 (1.68%)
Ex-Dividend Date	Jun 15, 2026

Volume	5,721,600
Open	19.19
Previous Close	19.18
Day's Range	18.90 - 20.55
52-Week Range	18.09 - 35.58
Beta	-0.34
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 29, 2026

About Aurisco Pharmaceutical

Aurisco Pharmaceutical Co.,Ltd. engages in the research, development, production and sales of special complex APIs, pharmaceutical intermediates and preparations worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs. It also provides eplerenone, an API to treat cardiovascular diseases, lowering blood pressure, and treating heart failure; futicasone propionate, used for the treatment of asthma, respiratory tract diseases, and rhinitis; Teno...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 2,026
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 605116

Financial Performance

In 2025, Aurisco Pharmaceutical's revenue was 1.70 billion, an increase of 15.03% compared to the previous year's 1.48 billion. Earnings were 449.21 million, an increase of 26.61%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 10, 2026

Data Sources Report a data error